1. Medtech Insight

TAVR Researchers Look To Lower-Risk Patients, Less Data Demands

Edwards Lifesciences' Sapien 3 valve looked good at the annual American College of Cardiology conference, including in intermediate-risk patients. Could it mean less follow-up demands for future approvals? Meanwhile, Medtronic continued to press its status as the only company with a TAVR device shown superior to surgery.

Transcatheter aortic heart valve replacement device data presented at this year's American College of Cardiology Scientific Sessions support an accelerated development path for the next-generation Sapien device and expanded application of the technology to less acutely sick patients, TAVR researchers suggest.

Meanwhile, researchers tied to Medtronic PLC say data may now supports a change in clinical guidelines to favor CoreValve as superior to surgery.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight